| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
This compound is a chiral building block used in the preparation of 6-aminopyridin-3-ylthiazoles as a method of treating or ameliorating syndromes, disorders, or diseases related to rheumatoid arthritis or psoriasis. The (1R,3S) stereochemistry provides specific three-dimensional interactions with target proteins.
|
|---|---|
| ln Vitro |
In vitro, this compound is used as a building block for synthesizing bioactive molecules. Derivatives have been evaluated for the treatment of rheumatoid arthritis and psoriasis. The amino alcohol functionality enables further derivatization for drug discovery applications.
|
| ln Vivo |
In vivo activity data for this compound itself are limited as it is primarily a synthetic intermediate. However, derivatives synthesized from this intermediate have been investigated in animal models for the treatment of rheumatoid arthritis and psoriasis.
|
| Enzyme Assay |
For synthesis applications, the compound is used as a starting material for the preparation of 6-aminopyridin-3-ylthiazoles. The amino and hydroxyl groups undergo further chemical transformations. Reactions are carried out in organic solvents with appropriate reagents and catalysts.
|
| Cell Assay |
For cell-based studies, derivatives synthesized from this compound are evaluated in relevant cell lines. Cells are cultured in DMEM or RPMI-1640 with 10% FBS at 37°C in 5% CO₂. Cells are treated with synthesized compounds at 0.1-100 µM for 24-72 hours. Biological activity is assessed using appropriate assays such as MTT, ELISA, or cytokine assays.
|
| Animal Protocol |
For in vivo studies, derivatives are formulated in suitable vehicles and administered orally or intraperitoneally to rodents at 10-100 mg/kg. Efficacy is evaluated in models of rheumatoid arthritis or psoriasis. Blood samples are collected for pharmacokinetic analysis. Tissues are harvested for histopathological and biomarker analysis.
|
| ADME/Pharmacokinetics |
(1R,3S)-3-Aminocyclopentanol hydrochloride has a molecular weight of 137.61 g/mol and a molecular formula of C₅H₁₂ClNO. Purity is typically ≥97%. It typically exists as a solid at room temperature. It is soluble in water and polar organic solvents. Storage: at room temperature.
|
| Toxicity/Toxicokinetics |
Acute toxicity data are limited. Standard laboratory safety practices should be followed. The compound may cause skin and eye irritation upon contact. Proper personal protective equipment should be used. The hydrochloride salt form may be irritating to mucous membranes.
|
| Additional Infomation |
(1R,3S)-3-Aminocyclopentanol hydrochloride is a chiral cyclic amino alcohol used for the preparation of 6-aminopyridin-3-ylthiazoles as a method of treating or ameliorating syndromes, disorders, or diseases related to rheumatoid arthritis or psoriasis. It is a research chemical.
|
| Molecular Formula |
C5H12CLNO
|
|---|---|
| Molecular Weight |
137.61
|
| Exact Mass |
137.061
|
| CAS # |
1279032-31-3
|
| PubChem CID |
56845289
|
| Appearance |
Typically exists as solids at room temperature
|
| LogP |
1.361
|
| Hydrogen Bond Donor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
8
|
| Complexity |
65.1
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C1C[C@H](C[C@H]1N)O.Cl
|
| InChi Key |
SGKRJNWIEGYWGE-UYXJWNHNSA-N
|
| InChi Code |
InChI=1S/C5H11NO.ClH/c6-4-1-2-5(7)3-4;/h4-5,7H,1-3,6H2;1H/t4-,5+;/m0./s1
|
| Chemical Name |
(1R,3S)-3-aminocyclopentan-1-ol;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.2669 mL | 36.3346 mL | 72.6691 mL | |
| 5 mM | 1.4534 mL | 7.2669 mL | 14.5338 mL | |
| 10 mM | 0.7267 mL | 3.6335 mL | 7.2669 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
